相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Whitehawk Therapeutics presented two real-world analyses at WCLC 2026 showing PTK7 expression remains largely stable in EGFR wild-type lung adenocarcinoma after standard-of-care therapy. - PTK7 showed less treatment-associated variation than late-stage ADC targets MET, PD-L1 and ITGB6, and was consistent across tumors with or without other actionable genomic alterations. - A separate analysis found PTK7 expression was not independently associated with real-world overall or progression-free survival, supporting it as a target-engagement biomarker rather than a prognostic marker. - The findings reinforce the rationale for HWK-007, a PTK7-directed next-generation ADC in an ongoing Phase 1 trial in EGFR wild-type NSCLC, platinum-resistant ovarian and endometrial cancer.
- Transcenta Therapeutics and its subsidiary HJB granted WuXi Biologics a non-exclusive license to the HiCB continuous bioprocessing platform and ExcelPro cell culture media. - Transcenta will receive an upfront payment of RMB 10 million plus milestone payments tied to specified conditions under the agreement. - WuXi Biologics becomes Transcenta's strategic partner for CMC development and supporting molecules across its therapeutic antibody pipeline. - The HiCB platform combines intensified continuous perfusion upstream processing with hybrid continuous downstream purification to boost productivity over conventional fed-batch methods.
- The global viral clearance market is valued at USD 1.0 billion in 2026 and is forecast to grow at a 16.9% CAGR, reaching USD 4.8 billion by 2036. - Viral removal methods, including filtration and chromatography, are projected to account for 51.0% of method demand in 2026, while recombinant proteins represent 34.0% of application demand. - FDA adoption of ICH Q5A(R2) in January 2024 has expanded risk-based viral safety validation requirements across established biologics and emerging modalities. - South Korea leads country-level growth at a 17.8% CAGR, supported by concentrated commercial biomanufacturing capacity projected to exceed 2.14 million liters by 2030.
- Transcenta agreed to sell its Hangzhou GMP manufacturing assets to WuXi Biologics for RMB 190.0 million, a modest discount to an independent appraisal of RMB 198.8 million. - Intellectual property including the HiCB continuous bioprocessing platform and ExcelPro cell culture media was excluded from the disposal and retained by Transcenta. - One month later, Transcenta licensed HiCB and ExcelPro non-exclusively to WuXi Biologics for RMB 10 million upfront plus milestones, making WuXi its strategic CMC partner. - Proceeds will fund pipeline development, including the anti-Claudin18.2 antibody osemitamab (TST001) advancing toward a global Phase III trial in gastric and gastroesophageal junction cancer.
- WuXi Biologics was featured in BioPharma APAC's "Top 26 - Companies Leading Sustainable Biopharma Practices in 2026" for its Green CRDMO solution and sustainability performance. - The Company's Green CRDMO integrates sustainability across research, development, manufacturing, and operations, with SBTi-validated near-term, long-term, and net-zero targets including net-zero emissions by 2050. - Key technologies such as WuXiUI™ and single-use technology reduce lifecycle environmental impacts by up to 60% and product carbon footprint per gram of protein by up to 80%. - WuXi Biologics holds top ESG ratings including MSCI AAA, EcoVadis Platinum, and CDP "A List" recognition, underscoring global stakeholder confidence in its sustainability strategy.
- The global fill-finish manufacturing market reached roughly US$11 billion in 2025, with more than US$27 billion committed to expanding sterile capacity across 2024–2025 alone. - The GLP-1 boom has displaced non-GLP-1 sterile products from existing filling lines, forcing sponsors of antibodies, vaccines, and specialty injectables to seek new manufacturing partners. - Asia-Pacific is building isolator-first, device-aware fill-finish capacity faster than any other region, though equipment qualification lead times of 12–18 months mean most expansions will not be operational until 2027–2028. - The revised EU GMP Annex 1 has raised the regulatory floor globally, making the Contamination Control Strategy a mandatory, inspection-ready system that directly constrains throughput and batch risk.
- The global continuous bioprocessing market was valued at USD 386.89 million in 2025 and is forecast to grow at a CAGR of 17.44% through 2034. - Monoclonal antibodies accounted for the largest application segment at 35.94% market share in 2025, reflecting the dominance of mAb manufacturing. - North America led the market with a 38.65% revenue share in 2025, while Asia Pacific is expected to grow fastest at a 19.10% CAGR. - Key industry developments include Thermo Fisher's $4.0 billion acquisition of Solventum's Purification & Filtration business in September 2025.
- The US Department of Defense added WuXi AppTec to its Section 1260H list of "Chinese military companies," triggering provisions under the Biosecure Act. - WuXi AppTec, which generates three-quarters of its revenue from the US, has denied any association with the Chinese government and plans to appeal the designation. - Under the Biosecure Act, US companies with preexisting contracts have a 5-year transition period starting in 2028, but analysts warn supply chain disruptions could begin much earlier. - Analysts suggest European and North American competitors such as Bachem, PolyPeptide Group, Charles River Laboratories, and Evotec could benefit from the shift away from WuXi AppTec.
- A new Council on Foreign Relations report identifies three structural archetypes of U.S. pharmaceutical dependence on China, warning of peacetime weaponization risks comparable to rare-earth mineral coercion. - China controls 94% of amoxicillin starting materials, 74% of heparin supply, and 70% of acetaminophen, with upstream choke points rendering downstream diversification ineffective for essential generic medicines. - Chinese firms now hold approximately 32 of 55 late-stage monoclonal antibody programs globally, and China biotech licensing reached $137.7 billion in 2025, signaling competitive displacement across the biologics value chain. - The report proposes a layered policy framework combining strategic reserves, allied partnerships, mandatory country-of-origin labeling, and targeted tariffs to mitigate risks before a crisis makes decades of inaction unavoidable.
- Whitehawk Therapeutics presented real-world analysis at ASCO 2026 demonstrating that SEZ6 expression in small cell lung cancer exceeds approved and emerging ADC targets by at least 3-fold compared to HER2, B7-H3, DLL3, PD-L1 and PD-1. - The analysis revealed SEZ6 expression is highest in SCLC-A and SCLC-N molecular subtypes, which account for approximately 90% of all SCLC cases and are characterized by high neuroendocrine transcription factor expression. - SEZ6 expression positively correlates with DLL3 across neuroendocrine carcinomas, indicating potential for combination therapy approaches with existing DLL3-targeted treatments. - The company plans to submit an Investigational New Drug application for its biparatopic SEZ6-directed ADC HWK-206 in mid-2026, with Phase 1 trials expected to begin in Q3 2026.
